Section of Periodontology, Department of Oral Health Sciences, KU Leuven and Dentistry, University Hospitals, Leuven, Belgium.
Department of Periodontology, Faculty of Dentistry, Cukurova University, Adana, Turkey.
BMC Oral Health. 2021 Sep 29;21(1):485. doi: 10.1186/s12903-021-01817-4.
Choline-stabilized orthosilicic acid (CS-OSA) was previously found to stimulate bone collagen formation in osteopenia and to improve biomarkers of cartilage degradation in knee osteoarthritis. The aim of the present study was to investigate the effect of oral administration of CS-OSA on clinical symptoms of peri-implantitis and the associated bone loss.
Twenty-one patients with peri-implantitis were randomized in CS-OSA or placebo groups. After initial clinical and cone beam computed tomography (CBCT) measurements [probing pocket depth (PPD), bleeding on probing (BOP), mucosal recession (REC), distance from implant shoulder to alveolar crest (IS-AC) and distance from implant shoulder to first bone-to-implant contact (IS-BIC)], flap operations were performed at the peri-implantitis sites. All patients were instructed to use either placebo or CS-OSA capsules twice a day for 1 year. Measurements were repeated 6 and 12 months after randomization.
The data of 18 patients (36 implants) were used in the per protocol analysis. PPD and BOP improved significantly (p < 0.05) compared to baseline for both groups after 6 and 12 months. However, REC significantly increased in the placebo group but not in the CS-OSA group. The change in REC over 6 and 12 months was significantly different between groups (p < 0.01). IS-BIC and IS-AC measurements remained stable in the CS-OSA group whereas in the placebo group, both parameters increased significantly after 6 and 12 months. The change in IS-BIC over 12 months was significantly different between groups (p < 0.05).
The results of this preliminary study suggest that CS-OSA may stabilize and even prevent further bone loss after surgical peri-implantitis treatment and support mucosal tissue healing. Trial registration The trial was retrospectively registered at ISRCTN registry, registration number: ISRCTN14348802, registration date: 24/06/2020.
先前的研究发现,胆碱稳定的正硅酸(CS-OSA)可刺激骨质疏松症中的骨胶原蛋白形成,并改善膝骨关节炎中软骨降解的生物标志物。本研究旨在探讨口服 CS-OSA 对种植体周围炎的临床症状及相关骨丢失的影响。
21 例种植体周围炎患者随机分为 CS-OSA 组或安慰剂组。在初始临床和锥形束 CT(CBCT)测量[探诊深度(PPD)、探诊出血(BOP)、黏膜退缩(REC)、种植体肩到牙槽嵴的距离(IS-AC)和种植体肩到第一次骨-种植体接触的距离(IS-BIC)]后,在种植体周围炎部位进行翻瓣手术。所有患者均被指示每日使用安慰剂或 CS-OSA 胶囊两次,持续 1 年。在随机分组后 6 个月和 12 个月重复测量。
在按方案分析中,18 例患者(36 个种植体)的数据被用于分析。两组患者在 6 个月和 12 个月时与基线相比,PPD 和 BOP 均显著改善(p<0.05)。然而,REC 在安慰剂组中显著增加,而在 CS-OSA 组中则没有。6 个月和 12 个月时,两组间 REC 的变化差异有统计学意义(p<0.01)。CS-OSA 组的 IS-BIC 和 IS-AC 测量值保持稳定,而在安慰剂组中,这两个参数在 6 个月和 12 个月后均显著增加。12 个月时 IS-BIC 的变化在两组间差异有统计学意义(p<0.05)。
这项初步研究的结果表明,CS-OSA 可能在种植体周围炎治疗后稳定甚至防止进一步的骨丢失,并支持黏膜组织愈合。
该试验在 ISRCTN 注册中心进行了回顾性注册,注册号为 ISRCTN84600242,注册日期为 2020 年 6 月 24 日。